Drug Profile
Fluticasone propionate controlled release - Eupraxia Pharmaceuticals
Alternative Names: EP 104IAR; EP-104; EP-104GI; Fluticasone propionate - EupraxiaLatest Information Update: 08 Feb 2024
Price :
$50
*
At a glance
- Originator Eupraxia Pharmaceuticals
- Class Analgesics; Androstadienes; Anti-inflammatories; Antiallergics; Antiasthmatics; Eye disorder therapies; Fluorinated steroids; Glucocorticoids; Inorganic sulfur compounds; Small molecules; Steroids
- Mechanism of Action Glucocorticoid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Pain
- Phase I/II Eosinophilic oesophagitis
Most Recent Events
- 05 Feb 2024 Updated efficacy and adverse events data from a phase Ib/IIa RESOLVE trial in Eosinophilic oesophagitis released by Eupraxia Pharmaceuticals
- 01 Feb 2024 Phase-III clinical trials in Pain (Intra-articular)
- 01 Feb 2024 Eupraxia Pharmaceuticals completes an End-of-Phase 2 meeting with the US FDA for the phase III development program in Pain